MA32911B1 - Derives de benzothiazole convenant comme agents agents anticancereux - Google Patents

Derives de benzothiazole convenant comme agents agents anticancereux

Info

Publication number
MA32911B1
MA32911B1 MA33985A MA33985A MA32911B1 MA 32911 B1 MA32911 B1 MA 32911B1 MA 33985 A MA33985 A MA 33985A MA 33985 A MA33985 A MA 33985A MA 32911 B1 MA32911 B1 MA 32911B1
Authority
MA
Morocco
Prior art keywords
agents
benzothiazole derivatives
anticancer
formula
relates
Prior art date
Application number
MA33985A
Other languages
Arabic (ar)
English (en)
Inventor
Masanori Okaniwa
Terufumi Takagi
Masaaki Hirose
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32911(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32911B1 publication Critical patent/MA32911B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un dérivé hétérocyclique fusionné présentant une forte activité inhibitrice de Raf. L'invention concerne ainsi un composé représenté par la formule (I) ou l'un de ses sels. Dans cette formule (I), chaque symbole est tel que défini dans les présentes spécifications.
MA33985A 2008-12-02 2011-06-30 Derives de benzothiazole convenant comme agents agents anticancereux MA32911B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008307581 2008-12-02
JP2009125256 2009-05-25
PCT/JP2009/070447 WO2010064722A1 (fr) 2008-12-02 2009-12-01 Dérivés de benzothiazole convenant comme agents anticancéreux

Publications (1)

Publication Number Publication Date
MA32911B1 true MA32911B1 (fr) 2011-12-01

Family

ID=42026212

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33985A MA32911B1 (fr) 2008-12-02 2011-06-30 Derives de benzothiazole convenant comme agents agents anticancereux

Country Status (40)

Country Link
US (2) US8143258B2 (fr)
EP (1) EP2358689B9 (fr)
JP (1) JP5640014B2 (fr)
KR (1) KR101639092B1 (fr)
CN (1) CN102300854B (fr)
AR (1) AR074435A1 (fr)
AU (1) AU2009323274B2 (fr)
BR (1) BRPI0922109A2 (fr)
CA (1) CA2745144C (fr)
CL (1) CL2011001299A1 (fr)
CO (1) CO6400140A2 (fr)
CR (1) CR20110366A (fr)
CY (1) CY1117178T1 (fr)
DK (1) DK2358689T5 (fr)
DO (1) DOP2011000165A (fr)
EA (1) EA019447B1 (fr)
EC (1) ECSP11011165A (fr)
ES (1) ES2557304T3 (fr)
GE (1) GEP20146003B (fr)
HR (1) HRP20151370T1 (fr)
HU (1) HUE026491T4 (fr)
IL (1) IL213184A0 (fr)
JO (1) JO3101B1 (fr)
MA (1) MA32911B1 (fr)
ME (1) ME02331B (fr)
MX (1) MX2011005836A (fr)
MY (1) MY150989A (fr)
NZ (1) NZ593759A (fr)
PE (1) PE20110588A1 (fr)
PL (1) PL2358689T3 (fr)
PT (1) PT2358689E (fr)
RS (1) RS54370B9 (fr)
SG (1) SG171426A1 (fr)
SI (1) SI2358689T1 (fr)
SM (1) SMT201500316B (fr)
TN (1) TN2011000280A1 (fr)
TW (1) TWI436987B (fr)
UY (1) UY32281A (fr)
WO (1) WO2010064722A1 (fr)
ZA (1) ZA201104659B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689514C (fr) * 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Composes heterobicycliques comme inhibiteurs de kinase
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
EP2399921B1 (fr) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Composé hétérocyclique et applications
WO2013138753A1 (fr) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Promédicaments de riluzole et leur méthode d'utilisation
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
WO2014206344A1 (fr) 2013-06-28 2014-12-31 Beigene, Ltd. Composés amides tricycliques condensés comme inhibiteurs de kinases multiples
KR102272606B1 (ko) 2013-06-28 2021-07-05 베이진 엘티디 Raf 키나아제 및/또는 raf 키나아제 이량체 저해제로서 융합 트리시클릭 우레아 화합물
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103382190B (zh) * 2013-07-16 2015-01-14 浙江医药高等专科学校 一类噻唑并环己烷类化合物、其制备方法和用途
CN103435572B (zh) * 2013-07-16 2015-02-04 浙江医药高等专科学校 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CA2940144C (fr) 2014-02-20 2023-06-13 Cornell University Derives d'indazol-3-yl substitues et compositions pharmaceutiques connexes utiles comme inhibiteurs de la fascine
DK3169815T3 (da) 2014-07-15 2021-02-15 Ontario Institute For Cancer Res Fremgangsmåder og indretninger til forudsigelse af anthracyclinbehandlingseffektivitet
EP3236966B1 (fr) * 2014-12-23 2020-08-12 DOT Therapeutics-1, Inc. Combinaison d'inhibiteurs de raf et de taxanes
WO2017066664A1 (fr) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Polythérapie comprenant un inhibiteur de raf pour le traitement du cancer colorectal
WO2017165491A1 (fr) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Utilisation d'un antagoniste de pd-1 et d'un inhibiteur de raf dans le traitement du cancer
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
CN109053630B (zh) * 2018-08-22 2022-04-01 中国人民解放军第二军医大学 一种苯并噻唑类衍生物及其用途
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (fr) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020232445A1 (fr) * 2019-05-16 2020-11-19 The Regents Of The University Of California Modulateurs des voies de biosynthèse des nucléotides de pyrimidine
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN112094248B (zh) * 2020-09-17 2023-05-12 中国人民解放军海军军医大学 一种取代苯并噻唑类化合物及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086320A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Formes et compositions d'inhibiteurs de jak2
CA3234638A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
CN115724837B (zh) * 2022-10-26 2024-07-23 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399026A (en) 1941-02-06 1946-04-23 Chem Ind Basel Amides of 2-aminoarylenethiazoles
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6093728A (en) 1997-09-26 2000-07-25 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
CZ299125B6 (cs) * 1999-01-13 2008-04-30 Bayer Corporation Difenylové mocoviny substituované omega-karboxyarylovou skupinou jako inhibitory rafkinázy, jejich použití a farmaceutické kompozice s jejich obsahem
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP3519368B2 (ja) 1999-01-22 2004-04-12 麒麟麦酒株式会社 キノリン誘導体およびキナゾリン誘導体
CA2377771A1 (fr) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Composes heterocycliques et leurs applications en medecine
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
DE122008000002I1 (de) 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
JP2003525936A (ja) 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
CZ2003182A3 (cs) 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
EP1318992B1 (fr) 2000-09-21 2005-07-27 Smithkline Beecham Plc Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
EP1341771A2 (fr) 2000-11-29 2003-09-10 Glaxo Group Limited Composes chimiques
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
EP1432703A1 (fr) 2001-09-05 2004-06-30 Smithkline Beecham Plc Derives heterocycles de carboxamide utilises comme inhibiteurs de raf kinase
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10334663A1 (de) * 2003-07-30 2005-03-10 Merck Patent Gmbh Harnstoffderivate
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
AU2005244736B2 (en) 2004-05-07 2012-06-28 Exelixis Patent Company Llc Raf modulators and methods of use
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006071035A1 (fr) 2004-12-31 2006-07-06 Lg Life Sciences, Ltd. Nouveaux derives de ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide
WO2006076376A1 (fr) 2005-01-11 2006-07-20 Medicinova, Inc. Traitement topique de tumeurs solides et de la neovascularisation oculaire
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007058482A1 (fr) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Inhibiteurs de la proteine kinase
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
JP5238697B2 (ja) 2006-08-04 2013-07-17 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2058309A4 (fr) 2006-08-04 2010-12-22 Takeda Pharmaceutical Composé hétérocyclique à cycles fusionnés
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
WO2008084873A1 (fr) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation Dérivé oxime
CN101260106A (zh) * 2007-03-06 2008-09-10 中国药科大学 Raf激酶抑制剂及其制备方法和用途
WO2008125633A2 (fr) 2007-04-13 2008-10-23 Rikshospitalet - Radiumhospitalet Hf Traitement et diagnostic du cancer métastatique de la prostate par des inhibiteurs de récepteur de facteur de croissance epidermique (egfr)
WO2008141275A1 (fr) 2007-05-11 2008-11-20 The Johns Hopkins University Biomarqueurs pour mélanomes
JP2010528032A (ja) 2007-05-23 2010-08-19 ノバルティス アーゲー 甲状腺癌の処置のためのｒａｆ阻害剤
CA2689514C (fr) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Composes heterobicycliques comme inhibiteurs de kinase
JP2008307581A (ja) 2007-06-15 2008-12-25 Sanyo Special Steel Co Ltd 管材の洗浄装置
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (fr) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
JP2009125256A (ja) 2007-11-22 2009-06-11 Kandado:Kk 安眠枕
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
US20090275546A1 (en) 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
HUE026491T2 (en) 2016-06-28
AR074435A1 (es) 2011-01-19
HRP20151370T1 (hr) 2016-01-15
EA019447B1 (ru) 2014-03-31
JP5640014B2 (ja) 2014-12-10
CN102300854A (zh) 2011-12-28
DK2358689T5 (en) 2016-10-10
NZ593759A (en) 2012-07-27
CY1117178T1 (el) 2017-04-05
MX2011005836A (es) 2011-06-17
SMT201500316B (it) 2016-01-08
CL2011001299A1 (es) 2012-01-13
CN102300854B (zh) 2015-01-07
KR101639092B1 (ko) 2016-07-12
DK2358689T3 (en) 2015-12-14
RS54370B9 (sr) 2020-01-31
SG171426A1 (en) 2011-07-28
DOP2011000165A (es) 2011-06-30
TWI436987B (zh) 2014-05-11
CA2745144A1 (fr) 2010-06-10
EP2358689B1 (fr) 2015-09-30
GEP20146003B (en) 2014-01-10
PE20110588A1 (es) 2011-09-08
PT2358689E (pt) 2015-12-30
AU2009323274B2 (en) 2015-09-17
IL213184A0 (en) 2011-07-31
MY150989A (en) 2014-03-31
HUE026491T4 (en) 2017-07-28
UY32281A (es) 2010-06-30
KR20110091039A (ko) 2011-08-10
US8143258B2 (en) 2012-03-27
ECSP11011165A (es) 2011-07-29
EP2358689A1 (fr) 2011-08-24
CA2745144C (fr) 2017-10-03
PL2358689T3 (pl) 2016-03-31
WO2010064722A1 (fr) 2010-06-10
JO3101B1 (ar) 2017-09-20
US20120214855A1 (en) 2012-08-23
BRPI0922109A2 (pt) 2020-09-01
EA201170735A1 (ru) 2011-12-30
US8497274B2 (en) 2013-07-30
CO6400140A2 (es) 2012-03-15
ME02331B (fr) 2016-04-28
TW201024272A (en) 2010-07-01
JP2012510467A (ja) 2012-05-10
EP2358689B9 (fr) 2016-08-03
AU2009323274A1 (en) 2011-07-07
HK1161236A1 (zh) 2012-08-24
SI2358689T1 (sl) 2016-01-29
US20100216810A1 (en) 2010-08-26
RS54370B1 (sr) 2016-04-28
ZA201104659B (en) 2012-08-29
TN2011000280A1 (en) 2012-12-17
ES2557304T3 (es) 2016-01-25
CR20110366A (es) 2011-08-29

Similar Documents

Publication Publication Date Title
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
MA31770B1 (fr) Derives pyrrolidine dione spiroheterocyclique utiles en tant que pesticides.
MA31759B1 (fr) Compose amide
MA33330B1 (fr) Quinazolines substituées comme fongicides
MA46337B1 (fr) Composé de pyridine
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
WO2018182051A8 (fr) Inhibiteurs d'ip6k
EA201070994A1 (ru) Конденсированное гетероциклическое производное и его применение
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
MA33519B1 (fr) Hétérocycles microbicides
MA31690B1 (fr) Nouveaux fongicides
MA28076A1 (fr) Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
EA201070186A1 (ru) Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
MA32903B1 (fr) Inhibiteurs de proteine-kinases
RU2711869C3 (ru) Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
SMAP201100019A (it) Composti organici.
CO6190578A2 (es) Novedosos derivados de imidazol
MA32296B1 (fr) Derives de piperidine 3,4-substitues comme inhibiteurs de la renine
MA37719A1 (fr) Dérivés de pyrimidinone en tant qu'agents anti-malaria
EP1650194A4 (fr) Inhibiteur de la proteine kinase
MA32553B1 (fr) Composition pharmaceutique solide